News

23. 8. 2021 VUOS have developed several quinolone-based intermediates for pharmaceutical use

The process was developed in laboratory and the amounts can be scale up according to customers´request. Examples of derivatives are given below:

15. 7. 2022 VUOS have developed several 1,4-disubstituted imidazole and benzimidazole intermediates for pharmaceutical use

The process was developed in laboratory and the amounts can be scale up according to customers´request. Examples of derivatives are given below:

4. 8. 2022 VUOS has developed synthesis of THICA (N, N`, N``-trihydroxyisocyanuric acid, CAS 143435-52-3)

• highly efficient carbon radical producing (CRPC) catalyst for radical reactions, especially oxidation
• higher catalytic activity than conventional NHPI (N-hydroxyphthalimide)
• available from grams to kilograms in stock
• larger amount on demand